Cao Jun, Yu Yaner, Zhou Yangkun, Ji Qing, Qian Wenkang, Jia Dongdong, Jin Gu, Qi Yajun, Li Xin, Li Ningning, Li Tao, Fang Meiyu, Jin Hongchuan
Sir Run Run Shaw Hospital, Medical School of Zhejiang University, Hangzhou, China.
Key Laboratory of Head and Neck Cancer Translational Research of Zhejiang Province, Department of Rare and Head and Neck Oncology, Institute of Cancer Research and Basic Medical Sciences of Chinese Academy of Sciences, Cancer Hospital of University of Chinese Academy of Sciences, Zhejiang Cancer Hospital, Hangzhou, China.
Front Oncol. 2022 Oct 20;12:942258. doi: 10.3389/fonc.2022.942258. eCollection 2022.
Sinonasal mucosal melanoma (SNMM) originates from melanocytes. Currently, the main treatment methods, including surgery, radiotherapy and chemotherapy, have little effect on the recurrence and metastasis of SNMM. However, targeted therapy may be a breakthrough in treating SNMM.
A SNMM patient with ROS1 fusion received 250mg Crizotinib capsule (2 times a day, 1 tablet each time) therapy.
The patient achieved partial remission after 4 months of treatment and complete remission after 8 months of treatment.
Our findings suggest that crizotinib can be an option to improve overall survival and quality of life of patients with metastatic ROS1-fusion SNMM. We believe that our report will provide insights for the application of crizotini in the treatment of melanoma.
鼻窦黏膜黑色素瘤（SNMM）起源于黑素细胞。目前，包括手术、放疗和化疗在内的主要治疗方法对SNMM的复发和转移效果甚微。然而，靶向治疗可能是治疗SNMM的一个突破。
一名ROS1融合的SNMM患者接受了250mg克唑替尼胶囊治疗（每日2次，每次1片）。
患者在治疗4个月后达到部分缓解，8个月后达到完全缓解。
我们的研究结果表明，克唑替尼可以作为提高转移性ROS1融合SNMM患者总生存期和生活质量的一种选择。我们相信我们的报告将为克唑替尼在黑色素瘤治疗中的应用提供见解。
